All In Biotech

Drug Trial Radar · NCT01225562

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction

Last checked: Nov 20, 2026Latest source record: Jan 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 21,379 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

21,379

Actual

Start

Oct 2010

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 21, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

Conditions

  • Myocardial Infarction
  • Cardiovascular Death
  • Atherothrombosis
  • Stroke

Interventions

  • Ticagrelor 90 mgDrug

    Oral dose twice a day

  • Ticagrelor 60 mgDrug

    Oral dose twice a day

  • Ticagrelor PlaceboDrug

    Oral dose twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From RandomizationTime frame: Randomization up to 47 months
  2. Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of PatientsTime frame: First dosing up to 48 months

Locations

826 sites in 31 countries. Site status is shown where the registry gives one.

  • Research Site

    Alexander City, Alabama

  • Research Site

    Athens, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Jonesboro, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Alhambra, California

  • Research Site

    Anaheim, California

  • Research Site

    Bakersfield, California

  • Research Site

    Fountain Valley, California

  • Research Site

    La Mesa, California

  • Research Site

    Larkspur, California

  • Research Site

    Lomita, California

  • Research Site

    Los Angeles, California

  • Research Site

    Modesto, California

  • Research Site

    Newport Beach, California

  • Research Site

    Oakland, California

  • Research Site

    Oceanside, California

  • Research Site

    San Diego, California

  • Research Site

    San Marino, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Ventura, California

  • Research Site

    Westlake Village, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Littleton, Colorado

  • Research Site

    Loveland, Colorado

  • Research Site

    Hartford, Connecticut

  • Research Site

    Stamford, Connecticut

  • Research Site

    Newark, Delaware

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Boca Raton, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Coral Springs, Florida

  • Research Site

    Crystal River, Florida

  • Research Site

    Davie, Florida

Showing 40 of 826 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.